During the surgery, patients will receive clindamycin through a vein (intravenous administration). The medication will be given before the surgery begins and may be repeated if the operation lasts longer than 4 hours. The total daily amount of clindamycin will not exceed 1500 mg. Blood samples will be taken throughout the surgery to measure the amount of medication in the blood.

The study will also examine how the medication spreads in body tissues, particularly in the tissue around the heart. Researchers will monitor patients for three months after surgery to check for complications, including mediastinitis (a serious infection in the chest area between the lungs). They will also track how the body processes the medication and check for any unwanted effects.

The treatment will last for 5 days and will be given to patients who need heart surgery that uses a heart-lung bypass machine (a device that temporarily takes over the function of the heart and lungs during surgery). The study will look at whether these medications can help prevent several complications that can occur after surgery, including acute renal failure (sudden loss of kidney function), breathing problems, and the need for medications to maintain blood pressure.

Patients will receive either the combination of both medications or inactive substances that look the same as the real medications. The study will monitor patients for various side effects and complications for up to 28 days after their surgery. Some of the things being watched for include problems with salt levels in the blood, high blood sugar, infections, and any effects on the heart or brain.

The purpose of the study is to understand how inhaled nitric oxide affects the heart’s ability to pump blood and the blood flow in the lungs. The study will observe patients who are in the recovery phase right after their heart surgery. During the study, some patients will receive the inhaled gas, while others may receive a placebo. The effects on heart function and lung blood flow will be monitored to gather important information.

Participants in the study will be closely observed to see how their heart and lungs respond to the treatment. The study will help researchers learn more about the potential benefits of using nitric oxide in patients recovering from heart surgery, which could lead to improved care and outcomes in the future.

The purpose of the study is to investigate how these two types of plasma affect blood clotting in children who have heart surgery. The study will look at various factors related to blood clotting, such as the activity of certain proteins and the number of blood cells that help with clotting. These factors include protein S activity, α2-antiplasmin, and others like fibrinogen and thrombocyte count, which are important for understanding how well the blood can clot after surgery.

During the study, children undergoing heart surgery will receive either fresh frozen plasma or Omniplasma. The researchers will then measure the blood clotting factors shortly after the surgery to see if there are any differences between the two types of plasma. This information will help doctors understand which type of plasma might be better for children having heart surgery, ensuring they receive the best possible care.

The purpose of the study is to compare how this type of anesthesia affects breathing function after surgery. Participants will be randomly assigned to receive either the para-sternal block with Ropivacaine or a placebo. The study will monitor participants’ breathing and pain levels at various times after surgery, including the first day, the second day, and two months later. Breathing function will be measured using a test called spirometry, which checks how well the lungs are working by measuring the amount of air a person can exhale.

Throughout the study, researchers will also assess pain levels using a simple scale from 0 to 10, where 0 means no pain and 10 means the worst pain imaginable. Other aspects of recovery, such as the need for additional pain medication and any complications related to breathing, will also be monitored. The study aims to provide valuable information on whether the para-sternal block with Ropivacaine can improve recovery and comfort for patients after cardiac surgery.

During the study, participants will receive either Vitamin C or standard medical care. The treatment with Vitamin C will be administered for up to 7 days, with doses calculated based on body weight. The maximum daily dose is 200 mg per kilogram of body weight, with a total maximum dose of 1400 mg per kilogram over the treatment period.

The study will monitor various aspects of recovery after surgery, including heart function, complications, and the body’s inflammatory response. Patients will be followed during their hospital stay and for several months afterward to assess their recovery and overall health status. The treatment involves the medication Pascorbin, which contains Vitamin C as its active ingredient.

The purpose of the study is to determine if CUSTODIOL® is not inferior to another type of cardioplegia known as Buckberg blood cardioplegia. Patients will receive either CUSTODIOL® or Cardi-Braun Mantenimiento during their surgery. The study will monitor the patients for 90 days after the surgery to observe any major health events, such as heart attacks, kidney failure, or the need for medications to support heart function. Additionally, the study will look at other factors like the need for blood transfusions, the duration of mechanical ventilation, and any neurological complications.

Participants in the study will be closely monitored for any changes in their health, including the levels of a heart-related protein called Troponin I at 12 and 24 hours after surgery. The study will also compare the overall survival rates and the occurrence of conditions like atrial fibrillation, which is an irregular heartbeat, within 90 days post-surgery. This research aims to provide valuable insights into the best practices for protecting the heart during major cardiac surgeries.

Participants in the study will be given either the medication or a placebo, and their health will be monitored for a period of time after their surgery. The study will look at how often AKI occurs within seven days after surgery, as well as other health outcomes such as changes in kidney function, heart health, and recovery quality. The study will also track any side effects or complications that may arise from the treatment.

Throughout the study, various health measurements will be taken, including blood sugar levels, heart function, and kidney health. The study aims to provide valuable information on whether the medication can effectively protect the kidneys during and after heart surgery, potentially improving recovery and reducing the risk of serious complications. The trial is expected to continue until June 2025.

Participants in the trial will be randomly assigned to receive either Ilofotase alfa or a placebo, which is a substance with no active medication. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will monitor the participants’ kidney function by measuring levels of a substance called serum creatinine, which is a marker of kidney health, before and after the surgery.

Throughout the study, the safety of the participants will be closely monitored, and any side effects or adverse events will be recorded. The trial will also collect information on how the body processes Ilofotase alfa, known as pharmacokinetics. The study is expected to continue until 2025, with the aim of providing valuable insights into the potential benefits of Ilofotase alfa for patients undergoing heart surgery.